Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS).

---

Size: 7921px × 7464px
Photo credit: © Sciwriters / Alamy / Afripics
License: Royalty Free
Model Released: No

Keywords: -021, 021, 254740-64-2, 433540, chemical, dara-, formula, ps, ps-433540, re021, sparsentan, structure